Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Debt (2023 - 2025)

Historic Total Debt for Xeris Biopharma Holdings (XERS) over the last 3 years, with Q3 2025 value amounting to $219.5 million.

  • Xeris Biopharma Holdings' Total Debt rose 135758.78% to $219.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.5 million, marking a year-over-year increase of 135758.78%. This contributed to the annual value of $232.1 million for FY2024, which is 1050.6% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Total Debt stood at $219.5 million for Q3 2025, which was up 135758.78% from $218.6 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Total Debt high stood at $232.1 million for Q4 2024, and its period low was $420000.0 during Q2 2024.
  • Moreover, its 3-year median value for Total Debt was $17.5 million (2023), whereas its average is $106.9 million.
  • In the last 5 years, Xeris Biopharma Holdings' Total Debt tumbled by 9747.55% in 2024 and then skyrocketed by 5195380.95% in 2025.
  • Xeris Biopharma Holdings' Total Debt (Quarter) stood at $210.0 million in 2023, then grew by 10.51% to $232.1 million in 2024, then dropped by 5.45% to $219.5 million in 2025.
  • Its Total Debt was $219.5 million in Q3 2025, compared to $218.6 million in Q2 2025 and $229.8 million in Q1 2025.